Brief: Axim Biotechnologies announces phase IIa trial results validating its proprietary cannabinoid delivery method
21/11/2017 14:00
Nov 21 (Reuters) - Axim Biotechnologies Inc AXIM.PK :
* Announces phase IIa trial results validating its
proprietary
cannabinoid delivery method for treatment of irritable bowel
syndrome (IBS)
* Study results indicate that CanChew+ was well tolerated by
IBS
patients and no significant adverse side effects were observed
by any participants of trial
Source text for Eikon: ID:nGNXOHCAUa
Further company coverage: AXIM.PK
((Bangalore.newsroom@thomsonreuters.com; ;))
Recent news on Axim Biotechnologies
See all newsBrief: AXIM Biotechnologies Partners With Arizona State University To Determine Antibody Levels Against Covid-19
Brief: Axim Biotechnologies Inc Develops Next Generation Of Its Rapid Neutralizing Antibody Test For Covid-19
Brief: AXIM Biotechnologies To Acquire Technology Including
Brief: Axim® Biotechnologies Successfully Completes Point-Of-Care Clinical Trials On Its Rapid Covid-19 Neutralizing Antibody Test
Brief: Axim Biotechnologies Inc Says Filed A Provisional Patent For A First-In-Class Face Mask That Captures And Deactivates Sars-Cov-2